Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Korbling

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphomaI F Khouri, J Romaguera, H Kantarjian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 1, 1997
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patientsK van Besien, P Thall, M Korbling, et al.
Blood|December 12, 2001
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortalityI F Khouri, R M Saliba, S A Giralt, et al.
Bone Marrow Transplantation|August 12, 2009
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCTS O Ciurea, R Saliba, G Rondon, et al.
Bone Marrow Transplantation|June 13, 2000
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancerM L Donato, D Gershenson, C Ippoliti, et al.
Leukemia & Lymphoma|March 8, 2000
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphomaM L Donato, R E Champlin, K W Van Besien, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 24, 1996
Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapyE G Hanania, R E Giles, J Kavanagh, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphomaI F Khouri, J Romaguera, H Kantarjian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 1, 1997
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patientsK van Besien, P Thall, M Korbling, et al.
Blood|December 12, 2001
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortalityI F Khouri, R M Saliba, S A Giralt, et al.
Bone Marrow Transplantation|August 12, 2009
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCTS O Ciurea, R Saliba, G Rondon, et al.
Bone Marrow Transplantation|June 13, 2000
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancerM L Donato, D Gershenson, C Ippoliti, et al.
Leukemia & Lymphoma|March 8, 2000
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphomaM L Donato, R E Champlin, K W Van Besien, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 24, 1996
Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapyE G Hanania, R E Giles, J Kavanagh, et al.
Pageof 4